Posted on Tuesday, March 26th, 2013 | In Small & Micro Cap
Rainbow Coral this morning told investors that it is already searching for new targets that would benefit from adding licenses for the drug delivery protocols TheraKine and RBCC plan to roll out. TheraKline, developer of a revolutionary drug delivery platform that could soon make local delivery of biologic agents and small molecules safer and more effective, joint ventured with RBCC’s biotech subsidiary very recently.
As noted in today’s press release, the global market for drug delivery technologies is driven by biologics and medications that can’t be administered effectively through traditional means. It is believed by some experts that the worldwide market for the 10 most popular drug delivery technologies alone could grow to $81.5 billion in just two years.
Working hard to maximize the success of its latest partnership, RBCC is seeking out healthcare providers for whom TheraKine’s advanced sustained-release delivery system could yield significant returns for their clients. TheraKine has developed and patented novel, tunable technologies with the potential to enable selective, site-specific drug delivery, allowing for lower drug concentrations and significantly reducing the risk of drug toxicity.
“Licensing this incredible new platform is going to be one of the key opportunities to making this a successful partnership,” stated RBCC CEO Patrick Brown. “It’s a top priority for our company moving forward. The potential is limitless.”
For more information on RBCC’s initiatives, visit www.rainbowbiosciences.com
Let us hear your thoughts: Rainbow Coral Corp. Message Board
About QualityStocks (http://QualityStocks.net)
Our name, QualityStocks, emphasizes our commitment to connect subscribers with companies that have huge potential to succeed in the short and long-term future. We believe strong management and vision for the future are crucial for any company to be successful. Timing is everything and we help investors succeed by providing an objective, broad-based view of the SmallCap markets on a daily basis. Please see disclaimer on QualityStocks website: http://disclaimer.qualitystocks.net